<DOC>
	<DOCNO>NCT00080782</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , doxorubicin , work different way stop tumor cell divide stop grow die . Strontium-89 may relieve bone pain cause prostate cancer . Celecoxib may stop growth cancer stop blood flow tumor block enzyme necessary tumor cell growth . Combining doxorubicin strontium-89 celecoxib may kill tumor cell . PURPOSE : This randomized phase II trial study celecoxib together doxorubicin strontium-89 see well work compare doxorubicin strontium-89 alone treat patient progressive androgen-independent prostate cancer bone metastasis .</brief_summary>
	<brief_title>Doxorubicin Strontium-89 With Without Celecoxib Treating Patients With Progressive Androgen-Independent Prostate Cancer Bone Metastases</brief_title>
	<detailed_description>OBJECTIVES : - Compare time prostate-specific antigen progression patient progressive androgen-independent prostate cancer bone metastasis treat doxorubicin strontium chloride Sr 89 without celecoxib . OUTLINE : This randomize study . Patients stratify accord extent bone metastases bone scan ( &gt; 20 lesion vs ≤ 20 lesion ) quality response ( i.e. , decline prostate-specific antigen baseline ) prior induction chemotherapy ( ≥ 80 % v &lt; 80 % ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive doxorubicin IV 30 minute day 1 , 8 , 15 , 22 strontium chloride Sr 89 IV day 1 . Patients also receive oral celecoxib twice daily absence disease progression . - Arm II : Patients receive doxorubicin strontium chloride Sr 89 arm I . PROJECTED ACCRUAL : A total 70 patient ( 35 per treatment arm ) accrue study within 18 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis androgenindependent prostate cancer Osteoblastic metastases No predominant visceral metastasis Progressive disease response prior induction chemotherapy ( prostatespecific antigen decline least 50 % baseline 16 week treatment ) No symptomatic lymphadenopathy ( i.e. , scrotal pedal edema ) PATIENT CHARACTERISTICS : Age Any age Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other Adequate physiologic reserve PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy No prior radionuclide therapy Surgery Not specify Other No 3 prior cytotoxic treatment More 6 month since prior celecoxib rofecoxib</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>bone metastasis</keyword>
	<keyword>Progressive Androgen-Independent Prostate Cancer</keyword>
	<keyword>Metastron</keyword>
	<keyword>Sr-89</keyword>
	<keyword>Strontium-89</keyword>
	<keyword>strontium chloride Sr 89</keyword>
	<keyword>Celecoxib</keyword>
	<keyword>Celebrex</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Rubex</keyword>
	<keyword>Adriamycin</keyword>
</DOC>